RESULTS OF ANTIFIBROTIC THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B+C

Author:

Usychenko K.M.ORCID

Abstract

Modern antiviral therapy regimens for patients with chronic viral hepatitis aim to achieve either long-term suppression of pathogen replication (e.g., nucleoside analogs in chronic hepatitis B) or complete elimination of the virus (such as direct-acting antiviral drugs in chronic hepatitis C). However, antiviral agents do not have a significant impact on the complete restoration of biochemical processes or the prevention of further progression of morphological changes in the liver. These limitations emphasize the ongoing need for new therapeutic strategies that target the processes of fibrogenesis. The aim of the work is to assess the possibility of the effect of the drug "Bicyclol" on fibrotic changes in patients with chronic hepatitis B+C using a non-invasive scale of the rate of fibrosis. Materials and methods An analysis of the dynamics of 62 patients with chronic hepatitis B and C (HCV+C) was conducted. All patients received long-term antiviral therapy consisting of pegylated interferon for 48 weeks. In the main group (Group I), patients with chronic hepatitis B and C were prescribed the drug "Bicyclol" after completing antiviral treatment with interferon. The control group (Group II) followed the principles of proper nutrition and took traditional hepatoprotectors. Based on the identified correlations, a non-invasive scale was proposed to assess the individual risk of liver fibrosis progression. Research results Against the background of the use of an antiviral treatment regimen, the normalization of cytolysis indicators was observed in most patients with CHB+C, but in some patients it was short-lived. Treatment with the drug "Bicyclol" contributed to a further decrease in cytolysis indicators, in the vast majority of patients with CHB+C, the activity of ALT and AST reached the upper limit of the norm. In patients with CHB+C who received only basic treatment without an antifibrotic component, a tendency to maintain an elevated level of transaminases was observed. Conclusions. Thus, the use of the hepatoprotector "Bicyclol" for 12 months ensures a decrease in cytolysis in the liver, is accompanied by a decrease in the severity of fibrosis, and in some patients - its reverse development. The use of the proposed prognostic scale makes it possible to assess the need for early appointment of antifibrotic therapy.

Publisher

State Institution of Science Research and Practical Center

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference11 articles.

1. Tsentr hromadskoho zdorovia MOZ Ukrainy. Zvit za rezultatamylikuvannia virusnykh hepatytiv v 2020 rotsi [Public Health Center of the Ministry of Health of Ukraine. Report on the results of viral hepatitis treatment in 2020] [in Ukrainian]. https://phc.org.ua/sites/default/files/users/user90/A4_zvit_gepatit1021_online_zamina.pdf (Date of application: 24.01.2021)

2. European association for study of the liver. (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatology, (67), 370-398.

3. Fedorchenko S.V. (2018). Koynfektsyia HCV/HBV: monohrafyia. [HCV/HBV co-infection: monograph.] Kyiv: VSY "Medicine"; 120. [in Ukrainian].

4. Gerasun B.A., Gerasun O.B., Kryzhanovska M.A. (2011). Patohenetychni mekhanizmy tryvaloi persystentsii virusu hepatytu В. [Pathogenetic mechanisms of long-term persistence of hepatitis B virus]. Hepatology, (1), 14-25. [in Ukrainian].

5. Golubovskaya O.A., Merkulova Yu.V., Nosalskaya T.N. (2015) Bytsyklol. Mekhanyzmы realyzatsyy klynycheskoho эffekta. Farmakodynamyka. Klynycheskaia farmakolohyia. Obzor mnohotsentrovыkh klynycheskykh yssledovanyi Farmakodynamyka. Klynycheskaia farmakolohyia. Obzor mnohotsentrovыkh klynycheskykh yssledovanyi. [Bicyclol. Mechanisms of realization of the clinical effect. Pharmacodynamics. Clinical pharmacology. Overview of multicenter clinical studies Pharmacodynamics. Clinical pharmacology. Overview of multicenter clinical studies]. 61 Р. [in Ukrainian].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3